Drug Profile
Research programme: inhaled peptides - Boehringer Ingelheim/Syntonix
Latest Information Update: 25 Feb 2008
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Syntonix Pharmaceuticals
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 01 Feb 2007 Syntonix Pharmaceuticals has been acquired by Biogen Idec
- 08 Nov 2005 Preclinical trials in Undefined in Germany (Inhalation)
- 08 Nov 2005 Preclinical trials in Undefined in USA (Inhalation)